Alterity Therapeutics said that it has launched a phase 2 clinical trial of its lead candidate ATH434 in patients with multiple system atrophy (MSA).

According to the Australian biotech company, the mid-stage clinical trial is now open for patient enrolment in New Zealand.

Alterity Therapeutics believes that ATH434 lowers the toxic accumulation of α-synuclein, which is a pathological hallmark of multiple system atrophy. ATH434 is said to preserve nerve cells through the restoration of normal iron balance in the brain.

The Australian biotech company said that ATH434 can potentially address the underlying pathology of multiple system atrophy and preserve function in patients.

David Stamler — Alterity Therapeutics CEO said: “The advancement of our ATH434 program underscores our commitment to bring a much needed treatment to individuals with MSA.

“The opening of enrolment for our Phase 2 in New Zealand is an important first step for this clinical program, and I am grateful to our team and our investigators who supported the launch of the trial. Over the course of this year, we will expand the trial into other regions globally.”

  Alterity Therapeutics, ATH434, Australia, David Stamler, Multiple System Atrophy, New Zealand